Trial Profile
Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PONALLO
- 15 Feb 2024 Planned End Date changed from 1 Jun 2024 to 31 Dec 2024.
- 12 Dec 2023 Status changed to discontinued, according to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Protocol has been amended after the 14th patient to start ponatinib between day 100 and day 120 post-allo, because of excesssive hematopoietic toxicity, according to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition